Rallybio Corporation (NASDAQ:RLYB) Given Consensus Recommendation of “Reduce” by Brokerages

Shares of Rallybio Corporation (NASDAQ:RLYB) have earned an average rating of “Reduce” from the five analysts that are presently covering the company, Marketbeat Ratings reports. One analyst has rated the stock with a sell recommendation and four have assigned a hold recommendation to the company. The average 1-year price target among analysts that have covered the stock in the last year is $40.00.

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Rallybio in a report on Monday, December 29th.

Hedge Funds Weigh In On Rallybio

Institutional investors have recently added to or reduced their stakes in the business. Geode Capital Management LLC lifted its position in Rallybio by 1.2% during the fourth quarter. Geode Capital Management LLC now owns 248,005 shares of the company’s stock worth $170,000 after buying an additional 2,996 shares during the period. XTX Topco Ltd increased its stake in shares of Rallybio by 64.6% during the 4th quarter. XTX Topco Ltd now owns 97,313 shares of the company’s stock valued at $67,000 after acquiring an additional 38,205 shares during the last quarter. Susquehanna International Group LLP lifted its holdings in shares of Rallybio by 485.9% during the 3rd quarter. Susquehanna International Group LLP now owns 136,294 shares of the company’s stock worth $68,000 after acquiring an additional 113,031 shares during the period. Renaissance Technologies LLC lifted its holdings in shares of Rallybio by 16.9% during the 4th quarter. Renaissance Technologies LLC now owns 835,692 shares of the company’s stock worth $573,000 after acquiring an additional 120,892 shares during the period. Finally, Citadel Advisors LLC boosted its position in shares of Rallybio by 576.1% in the third quarter. Citadel Advisors LLC now owns 438,705 shares of the company’s stock worth $219,000 after acquiring an additional 373,821 shares during the last quarter. 90.34% of the stock is currently owned by institutional investors and hedge funds.

Rallybio Price Performance

NASDAQ:RLYB opened at $9.61 on Monday. The firm has a market cap of $50.74 million, a PE ratio of -3.71 and a beta of -1.13. The firm has a 50 day simple moving average of $5.36 and a 200-day simple moving average of $5.08. Rallybio has a 1-year low of $1.76 and a 1-year high of $10.70.

About Rallybio

Rallybio Therapeutics, Inc (NASDAQ: RLYB) is a clinical‐stage biotechnology company focused on developing and commercializing therapies for people living with rare genetic diseases. The company’s scientific approach leverages diverse modalities—including monoclonal antibodies, small molecules and enzyme replacement—to address high‐unmet‐need conditions in areas such as immunodeficiency, metabolic disorders and dermatologic diseases. Rallybio’s pipeline is designed to advance through registrational clinical trials with the goal of delivering first‐in‐class or best‐in‐class therapies to patients who currently have limited or no approved treatment options.

Among Rallybio’s lead programs is RBX‐100, an investigational therapy for congenital athymia, a rare pediatric immunodeficiency.